Randal Goldberg, MD
Advanced Heart Failure and Transplant Cardiology · New York, NYNPI 1063775419
Payments from drug & device makers
Across 147 payments — averaging $37.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Transmedics, Inc.$1K
- Novartis$448
- Daiichi Sankyo Inc.$284
- Boehringer Ingelheim$278
- Pfizer$271
- plus $2K from 23 others
Across 4 payments — averaging $1917.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$8K
What the payments were for
- Travel & lodging$1,04419%
- Food & beverage$4,44881%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 17 | $1,596 |
| Transmedics, Inc. | 1 | $1,044 |
| Novartis | 24 | $448 |
| Daiichi Sankyo Inc. | 14 | $284 |
| Boehringer Ingelheim | 13 | $278 |
| Pfizer | 12 | $271 |
| AstraZeneca | 9 | $193 |
| Actelion Pharmaceuticals US, Inc. | 10 | $171 |
| Alnylam Pharmaceuticals Inc. | 8 | $161 |
| Medtronic | 1 | $126 |
| Merck | 6 | $123 |
| Daxor Corporation | 1 | $102 |
| Johnson & Johnson | 5 | $93 |
| Lexicon Pharmaceuticals, Inc. | 4 | $87 |
| Irhythm Technologies, Inc. | 2 | $80 |
| E.r. Squibb & Sons, L.L.C. | 2 | $61 |
| Bayer | 3 | $55 |
| Kestra Medical Technology Services, Inc. | 2 | $54 |
| Cvrx, Inc. | 2 | $51 |
| Ancora Heart, Inc. | 1 | $39 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $36 |
| Scpharmaceuticals Inc. | 1 | $28 |
| Masimo Corporation | 1 | $25 |
| Baxter Healthcare | 1 | $23 |
| Bridgebio Pharma, Inc. | 1 | $19 |
| Sensible Medical Innovations Inc | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Amgen | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,099
- ORGAN CARE SYSTEM$1,044
- CardioMEMS HF System$159
- CARDIOMEMS$154
- HeartWare HVAD$126
- BVA-100$102
How this compares
$5,508 in reported general payments places this provider in the 35th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
See all advanced heart failure and transplant cardiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 36 | $64,905 |
| JardianceEmpagliflozin | 17 | $25,126 |
| FarxigaDapagliflozin Propanediol | 21 | $20,104 |
| Metoprolol Succinate | 45 | $860 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 14 | $214 |
| Spironolactone | 40 | $207 |
| Losartan Potassium | 20 | $152 |
| Atorvastatin Calcium | 17 | $108 |
| Carvedilol | 17 | $104 |
| Furosemide | 17 | $70 |
| Amlodipine Besylate | 11 | $39 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $448 | $64,90536 claims |
| Boehringer IngelheimJardiance | $278 | $25,12617 claims |
| AstraZenecaFarxiga | $193 | $20,10421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
Other advanced heart failure and transplant cardiology in New York
- Mathew MaurerNew York$5M
- Evelyn HornNew York$2.9M
- Johanna ContrerasNew York$1.4M
- Parag GoyalNew York$1.1M
- Nir UrielNew York$884K
- Tajinderpal SaraonNew York$618K
- Kelly AxsomNew York$502K
- Sean PinneyNew York$414K
- Yevgeniy BrailovskyNew York$339K
- James YoussefNew York$287K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.